Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 7/2014

01-07-2014 | Letter

Type 1 diabetes as an autoimmune disease: the evidence

Authors: Stavroula A. Paschou, Asimina Petsiou, Katerina Chatzigianni, Agathocles Tsatsoulis, George K. Papadopoulos

Published in: Diabetologia | Issue 7/2014

Login to get access

Excerpt

To the Editor: The recent commentary [1] on the role of autoimmunity in the pathogenesis of type 1 diabetes, in response to a consensus definition of insulitis in human type 1 diabetes [2], is an opportunity to review the evidence in favour of type 1 diabetes being an autoimmune disease, and the absence of any direct evidence to the contrary. …
Literature
1.
Donath MY, Hess C, Palmer E (2014) What is the role of autoimmunity in type 1 diabetes? A clinical perspective. Diabetologia 57:653–655PubMedCrossRef
2.
Campbell-Thompson ML, Atkinson MA, Butler AE et al (2013) The diagnosis of insulitis in human type 1 diabetes. Diabetologia 56:2541–2543PubMedCrossRef
3.
Cahill GF Jr, McDevitt HO (1981) Insulin-dependent diabetes mellitus: the initial lesion. N Engl J Med 304:1454–1465PubMedCrossRef
4.
Bluestone JA, Herold K, Eisenbarth G (2010) Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 464:1293–1300PubMedCrossRef
5.
Keymeulen B, Walter M, Mathieu C et al (2010) Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 53:614–623PubMedCrossRef
6.
Roep BO, Solvason N, Gottlieb PA et al (2013) Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8+ T cells in type 1 diabetes. Sci Transl Med 5:191ra82PubMedCrossRef
7.
Itoh N, Hanafusa T, Miyazaki A et al (1993) Mononuclear cell infiltration and its relation to the expression of major histocompatibility complex antigens and adhesion molecules in pancreas biopsy specimens from newly diagnosed insulin-dependent diabetes mellitus patients. J Clin Invest 92:2313–2322PubMedCentralPubMedCrossRef
8.
Fiaschi-Taesch NM, Kleinberger JW, Salim FG et al (2013) Cytoplasmic-nuclear trafficking of G1/S cell cycle molecules and adult human β-cell replication: a revised model of human β-cell G1/S control. Diabetes 62:2460–2470PubMedCrossRef
9.
La Torre D, Seppänen-Laakso T, Larsson HE et al (2013) Decreased cord-blood phospholipids in young age-at-onset type 1 diabetes. Diabetes 62:3951–39516PubMedCrossRef
10.
Hakonarson H, Grant SF, Bradfield JP et al (2007) A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 448:591–594PubMedCrossRef
11.
Cerosaletti K, Schneider A, Schwedhelm K et al (2013) Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+CD25hi T cells of type 1 diabetic and multiple sclerosis patients. PLoS One 8:e838116CrossRef
12.
13.
Sutherland DE, Goetz F, Sibley RK (1989) Recurrence of disease in pancreas transplants. Diabetes 38(suppl 1):85–87PubMedCrossRef
14.
15.
16.
Rao A, Kamani N, Filipovich A et al (2007) Successful bone marrow transplantation for IPEX syndrome following reduced intensity conditioning. Blood 109:383–385PubMedCrossRef
Metadata
Title
Type 1 diabetes as an autoimmune disease: the evidence
Authors
Stavroula A. Paschou
Asimina Petsiou
Katerina Chatzigianni
Agathocles Tsatsoulis
George K. Papadopoulos
Publication date
01-07-2014
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 7/2014
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-014-3229-5

Other articles of this Issue 7/2014

Diabetologia 7/2014 Go to the issue

Article

The incidence of diabetes among 0–34 year olds in Sweden: new data and better methods

Article

Calcium and phosphate concentrations and future development of type 2 diabetes: the Insulin Resistance Atherosclerosis Study

Research Letter

Evidence from a single individual that increased plasma GLP-1 and GLP-1-stimulated insulin secretion after gastric bypass are independent of foregut exclusion

In memoriam

Michaela Diamant, 11 April 1962–9 April 2014

Short Communication

Risk of pancreatitis in patients treated with incretin-based therapies

Article

Low TCR signal strength induces combined expansion of Th2 and regulatory T cell populations that protect mice from the development of type 1 diabetes
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits